I-Mab
A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.
IMAB | US
Overview
Corporate Details
- ISIN(s):
- US44975P1030
- LEI:
- Country:
- United States of America
- Address:
- SUITE 400, 2440 RESEARCH BLVD, 20850 ROCKVILLE
- Website:
- https://www.i-mabbiopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
I-Mab is a clinical-stage, global biopharmaceutical company focused on the discovery, development, and commercialization of innovative immunotherapies for cancer treatment. The company's pipeline features precision immuno-oncology agents, including bispecific antibodies such as Givastomig and Ragistomig. I-Mab is undergoing a strategic transformation to become a global biotech platform, emphasizing business development and translational clinical development to accelerate patient access to novel medicines. As part of this shift, the company has announced its intention to rebrand as NovaBridge Biosciences.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all I-Mab filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for I-Mab
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for I-Mab via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
%20Ltd/other/HUTCHMED_China_Ltd-logo.png){kind=logo}
